These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17691950)

  • 1. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery.
    Rai S; Paliwal R; Vaidya B; Gupta PN; Mahor S; Khatri K; Goyal AK; Rawat A; Vyas SP
    Curr Med Chem; 2007; 14(19):2095-109. PubMed ID: 17691950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted breast cancer nanotherapeutics: options and opportunities with estrogen receptors.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas S
    Crit Rev Ther Drug Carrier Syst; 2012; 29(5):421-46. PubMed ID: 22876809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.
    Vyas SP; Sihorkar V
    Adv Drug Deliv Rev; 2000 Sep; 43(2-3):101-64. PubMed ID: 10967224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptors and human disease.
    Deroo BJ; Korach KS
    J Clin Invest; 2006 Mar; 116(3):561-70. PubMed ID: 16511588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
    Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
    Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid-coupled liposomes for targeted delivery to tumor.
    Jain SK; Jain A; Gulbake A; Shilpi S; Khare P
    Ther Deliv; 2010 Aug; 1(2):345-57. PubMed ID: 22816137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The life and times of the estrogen receptors: an interim report.
    Albertazzi P; Purdie DW
    Climacteric; 2001 Sep; 4(3):194-202. PubMed ID: 11588942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogens and Coronary Artery Disease: New Clinical Perspectives.
    Meyer MR; Barton M
    Adv Pharmacol; 2016; 77():307-60. PubMed ID: 27451102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.
    He S; Nelson ER
    Maturitas; 2017 Oct; 104():29-35. PubMed ID: 28923174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: a perspective.
    Kumar S; Lata K; Mukhopadhyay S; Mukherjee TK
    Biochim Biophys Acta; 2010 Oct; 1800(10):1127-35. PubMed ID: 20434525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of polymer-drug conjugates in organ-specific delivery systems.
    Paramjot ; Khan NM; Kapahi H; Kumar S; Bhardwaj TR; Arora S; Mishra N
    J Drug Target; 2015 Jun; 23(5):387-416. PubMed ID: 25720345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research progress of polyamidoamine dendrimer in targeting drug delivery system].
    Ding RM; He H; Li J
    Yao Xue Xue Bao; 2011 May; 46(5):493-501. PubMed ID: 21800534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case for an Estrogen-iron Axis in Health and Disease.
    Hamad M; Bajbouj K; Taneera J
    Exp Clin Endocrinol Diabetes; 2020 Apr; 128(4):270-277. PubMed ID: 30978727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex.
    Yin JJ; Shumyak SP; Burgess C; Zhou ZW; He ZX; Zhang XJ; Pan ST; Yang TX; Duan W; Qiu JX; Zhou SF
    Int J Nanomedicine; 2015; 10():4717-30. PubMed ID: 26251594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the estrogen receptor using steroid-therapeutic drug conjugates (hybrids).
    Dao KL; Hanson RN
    Bioconjug Chem; 2012 Nov; 23(11):2139-58. PubMed ID: 23036054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular platforms for targeted drug delivery.
    Maso K; Grigoletto A; Vicent MJ; Pasut G
    Int Rev Cell Mol Biol; 2019; 346():1-50. PubMed ID: 31122392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of herbal bioactives through folate receptors: a novel concept to enhance intracellular drug delivery in cancer therapy.
    Gupta A; Kaur CD; Saraf S; Saraf S
    J Recept Signal Transduct Res; 2017 Jun; 37(3):314-323. PubMed ID: 28095746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen synthesis and signaling pathways during aging: from periphery to brain.
    Cui J; Shen Y; Li R
    Trends Mol Med; 2013 Mar; 19(3):197-209. PubMed ID: 23348042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
    van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
    J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.